Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 161 to 170 of 326 total matches.

Nebivolol (Bystolic) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Mar 10, 2008  (Issue 1281)
as well as beta-blocking effects, but unlike the other two drugs, which have alpha-blocking properties ...
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Med Lett Drugs Ther. 2008 Mar 10;50(1281):17-9 |  Show IntroductionHide Introduction

Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
. Netupitant selectively inhibits NK1 receptors and blocks the action of substance P, a neuropeptide ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK1) receptor antagonist netupitant and the serotonin-3 (5-HT3) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK1 receptor antagonist to be...
Med Lett Drugs Ther. 2015 Apr 27;57(1467):61-3 |  Show IntroductionHide Introduction

Celecoxib for Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 1999  (Issue 1045)
NSAIDs, in varying degrees, block both COX isoforms. Celecoxib, a diaryl substituted pyrazole, is a much ...
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.
Med Lett Drugs Ther. 1999 Jan 29;41(1045):11-2 |  Show IntroductionHide Introduction

Lyme Disease Vaccine

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999  (Issue 1049)
, neurologic (Bell’s palsy, radiculoneuropathy, meningitis) and cardiac (AV block, arrhythmias, myopericarditis ...
The first human vaccine for prevention of Lyme disease (LYMErix), has been approved by the FDA for use in patients 15 to 70 years old.
Med Lett Drugs Ther. 1999 Mar 26;41(1049):29-30 |  Show IntroductionHide Introduction

Cosmetic Use of Botulinum Toxin

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 1999  (Issue 1057)
as an alternative to cosmetic surgery. MECHANISM OF ACTION — Botulinum toxin blocks neuromuscular conduction ...
Botulinum toxin type A has been marketed in the USA since 1989 for treatment of strabismus and blepharospasm and has also been used to treat cervical dystonia and some other muscular disorders.
Med Lett Drugs Ther. 1999 Jul 16;41(1057):63-6 |  Show IntroductionHide Introduction

Argatroban For Treatment of Heparin-Induced Thrombocytopenia

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2001  (Issue 1097)
— Argatroban prevents and treats thrombosis by blocking the catalytic site of soluble and clot-bound thrombin ...
Argatroban, a small-molecule synthetic derivative of L-arginine, is a direct thrombin inhibitor approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT).
Med Lett Drugs Ther. 2001 Feb 5;43(1097):11-2 |  Show IntroductionHide Introduction

Caspofungin (Cancidas) For Aspergillosis

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001  (Issue 1108)
(Sporanox). MECHANISM OF ACTION — Echinocandins block the synthesis of β (1,3)-d-glucan, a polysaccharide ...
Caspofungin acetate(Cancidas) is the first of a new class of antifungals, the echinocandins. It has been approved by the FDA for treatment of invasive aspergillosis in patients who fail to respond to or are unable to tolerate other antifungal drugs such as amphotericin B and itraconazole.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):58-9 |  Show IntroductionHide Introduction

Botulinum Toxin for Cervical Dystonia

   
The Medical Letter on Drugs and Therapeutics • Jul 23, 2001  (Issue 1109)
A and type B toxins produced by Clostridium botulinum block cholinergic junctions at the motor endplate ...
Botulinum toxin type A (Botox - Allergan) and type B (Myobloc - Elan) are now approved by the FDA for treatment of cervical dystonia. Botulinum toxin type A has been approved since 1989 for treatment of strabismus and blepharospasm. It is also used cosmetically to reduce wrinkles on the face and neck.
Med Lett Drugs Ther. 2001 Jul 23;43(1109):63-4 |  Show IntroductionHide Introduction

Substituting For Cerivastatin (Baycol)

   
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001  (Issue 1113)
rhabdomyolysis. RISK OF MYOPATHY — "Statins" lower cholesterol levels by blocking HMG-CoA reductase, the enzyme ...
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
Med Lett Drugs Ther. 2001 Sep 17;43(1113):79-80 |  Show IntroductionHide Introduction

An Injectable Hyaluronic Acid (Restylane) for Wrinkles

   
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004  (Issue 1177)
per treatment site. A nerve block, topical analgesic cream and/or ice are suggested for numbing ...
An injectable gel of hyaluronic acid (Restylane) has been approved by the FDA for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Manufactured by Q-Med AB, a Swedish company, it has been used outside the US since 1996.
Med Lett Drugs Ther. 2004 Mar 1;46(1177):17-8 |  Show IntroductionHide Introduction